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Background: Blood stream tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB) is common among HIV-positive
patients, turning rapidly fatal unless detected and treated promptly. Blood culture is currently the standard test for the
detection of MTB in whole blood but results take weeks; patients deteriorate markedly and often die before a diagnosis of
blood stream TB is made. Rapid molecular tests on whole blood, with potential for same day diagnosis of blood stream TB
usually show low sensitivity due to the problem of insufficient MTB DNA template when extraction is performed directly
on low blood volumes. This study assessed the influence of blood volume on the sensitivity of a HyBeacon PCR
assay-the FluoroType® MTB (Hain Lifescience, Nehren, Germany) on direct detection of MTB in whole blood.
Methods: Prospective recruitment of HIV-positive patients with clinical suspicion of blood stream TB but not on
anti-TB or HIV drug treatment was done. Venous blood samples were collected and DNA extracted using the MolYsis
(Molzym, Bremen, Germany) methods; for study A, from duplicate 1 ml (42 patients) and for study B (31 patients) from
9 ml EDTA blood samples. The FluoroType® MTB PCR assay targeting an IS6110 sequence was performed and results
compared with blood culture.
Results: The diagnostic sensitivity and specificity of the FluoroType® MTB PCR in study A was 33% and 97%,
respectively. Corresponding values in study B were 71% and 96%, respectively. In both studies, one case each of
blood culture-negative blood stream TB was detected with the FluoroType® MTB PCR assay. The median time to
positivity of blood culture was 20.1 (range 12–32) for study A and 19.9 days (range 15–30) for study B.
Conclusion: Larger blood volumes (9 ml) improved and gave acceptable sensitivity of direct PCR diagnosis of
blood stream TB.
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In the late 1980s, it was discovered that infection with
the Human Immunodeficiency Virus (HIV) predisposed
individuals to defects in the cell-mediated and humoral
immunity resulting into susceptibility to blood stream
infections with Mycobacterium tuberculosis (MTB), and
to other pathogens such as non-typhoid salmonellae,
Streptococcus pneumoniae, Cryptococcus neoformans and
Staphylococcus aureus [1]. Since then, further studies* Correspondence: freddie.bwanga@case.edu
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unless otherwise stated.have demonstrated the critical role of blood stream TB
among the HIV patients [2-5]. Studies in Tanzania and
Uganda reported MTB to be the most frequently isolated
pathogen in 43% and 13% of positive blood cultures
among the HIV-positive febrile patients, respectively [3,5].
However, blood cultures for Mycobacterium tuberculosis -
a slow growing organism, requires around 3–6 weeks, a
time period during which patients deteriorate markedly
and may die before a diagnosis is made. Studies have re-
ported the 30-day mortality attributed to blood stream TB
to be at around 50% [5,6]. Thus, there is an urgent need
for novel tests for rapid diagnosis of blood stream TB,
particularly among the febrile HIV-positive patients.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tests such as the Cepheid Xpert MTB/RIF and Line probe
assays have been developed and approved by the WHO for
the direct diagnosis of tuberculosis or drug resistant tuber-
culosis, particularly in sputum [7,8]. However, these assays
are not adapted to whole blood and show poor diagnostic
sensitivity for detection of MTB in whole blood [9].
New pre-analytic approaches aim at increasing the assay
sensitivity through enrichment of microbial DNA from
blood samples. Two commercial systems are available for
this approach [10]. The LOOXTER (Analytic Jena, Jena,
Germany) uses a protein that binds to methylated sites
and thereby removes eukaryotic DNA providing enriched
prokaryotic DNA to molecular testing. The other system,
MolYsis (Molzym, Bremen, Germany) follows a protocol
that involves lysis of blood cells, nucleolytic degradation
of released human DNA and thereafter extraction and
enrichment of microbial DNA. Here, we compared
MolYsis-based extraction protocols for small (1 ml) and
large blood volumes (9 ml) with respect to an effect on
the detection sensitivity of mycobacteria by a HyBeacon
PCR assay, FluoroType® MTB (Hain Lifescience, Neh-
ren, Germany). For this purpose, blood from patients
who were HIV sero-positive and who had clinical fea-
tures of blood stream TB, as assessed by a senior infec-
tious diseases physician was analyzed.
Methods
Study design
This was a cross-sectional study with prospective patient
recruitment conducted in two sub studies (study A:
February 2012-May 2012 and study B: November 2012-Figure 1 Study summary chart.May 2013). The study was approved by the School of
Medicine Research and Ethics Committee of Makerere
University College of Health Sciences, approval number
REC REF 2011-253.
Study population
Participants in the studies were in-patients admitted at
the medical wards of Mulago national referral and teach-
ing Hospital Kampala, Uganda. The criteria for partici-
pant inclusion included HIV sero-positive, suspected on
clinical assessment (on/off fever with night sweats for at
least 2 consecutive weeks, loss of appetite associated
with weight loss) to have blood stream TB infection,
with or without features of pulmonary TB, and no his-
tory of TB or HIV drug treatment. Each study partici-
pant voluntarily signed a written consent to take part in
the study before specimen collection.
Specimen collection and processing
Specimens in this study included blood for direct myco-
bacteria PCR diagnosis and blood for MTB Blood cul-
ture as illustrated in Figure 1.
Blood for direct mycobacteria PCR diagnosis
During studies A and B, 2 and 10 mls, respectively of
whole blood were collected in EDTA vacutainers (BD,
Heidelberg, Germany) and then transferred within two
hours into UMD tubes (Molzym, Bremen, Germany). The
contents were mixed with the cryoprotectant (0.4 ml) in
the UMD tubes by vortexing thoroughly, and the tubes
frozen at minus 80°C at the TB laboratory of the Depart-
ment of Medical Microbiology Makerere University
Table 1 Patients in study A, positive for M. tuberculosis














bIn the case of positive results, at least one of the duplicate 1 ml samples
was positive.
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were later transferred to Bremen, Germany on dry ice
for DNA extraction and molecular testing.
DNA extraction
Prior to testing of the clinical blood specimens, we stud-
ied the influence of blood volume on the detection of
blood stream TB as follows: artificial spiking experi-
ments of EDTA blood samples (1 ml and 10 ml) from a
healthy individual were performed. For these experi-
ments (conducted 3 times), 1 ml and 10 ml of whole
blood was spiked with 30 and 3 cfu/ml of Mycobacter-
ium bovis BCG, respectively. The blood specimens were
inoculated with 10 μl of serial dilutions of a Mycobacter-
ium bovis BCG culture and extracted following the
protocols of the MTB-DNA Blood kit (Molzym).
For the clinical blood specimens, in study A, two 1 ml
aliquots of a thawed UMD tubes were run through the
small size sample DNA extraction protocol of the MTB-
DNA Blood kit. In study B, the UMD tubes were thawed
and the contents (9 ml) pipetted into a 50 ml centrifuge
tube supplied with the MTB-DNA Blood kit. The proto-
col for large size samples was followed, and DNA was
eluted with 0.1 ml of the supplied EB buffer.
Molecular analysis
DNA elutes from whole blood were analyzed using the
FluoroType® MTB (FT MTB; Hain Lifescience). The
assay consists of primers and a HyBeacon probe target-
ing the IS6110 element. The kit includes an internal
amplification control. The assay was run on an optical
thermo cycler (FluoroCycler®12, Hain Lifescience) with
melt curve analysis for the specific detection of M.
tuberculosis complex.
Blood culture for MTB
Five millilitres of whole blood were aseptically drawn
at venipuncture into BACTEC Myco/F-Lytic bottles
and incubated in the Bactec 9120 Automated Blood
Culture Instrument (Becton Dickinson, Sparks, Md) at
the TB laboratory-Department of Medical Microbiol-
ogy Makerere University College of Health Sciences
Kampala until positive or for 42 days for negative cul-
tures. Identification of M. tuberculosis from positive
reported cultures was done with the Capilia test (Tauns
Co. Ltd., Kamishima, Japan).
Results
Study population
HIV-positive patients aged 18 years and above, with
clinical symptoms and signs of tuberculosis (TB) were
used to determine the diagnostic sensitivity for detec-
tion of blood stream TB by PCR using small and large
blood volume DNA extracts compared to blood culturedetection. Study A was conducted from February 2012
until May 2012 and included 42 patients. Study B was
performed from November 2012 until May 2013 and
included 31 patients.
Influence of blood volume on the detection of blood
stream TB
Following the Mycobacterium bovis BCG spiking experi-
ments, the FT MTB test yielded a positive result in the
spiked blood samples in 3 of 3 repeat experimental
assays. Two of the three experiments were still positive
at 15 and 1.5 cfu/ml BCG with 1 ml and 10 ml extracts.
Study A results
The presence of MTB DNA in extracts from duplicate
1 ml blood samples was tested by FT MTB assay. Blood
stream TB was diagnosed by culture in 9/42 cases (21%).
FT MTB blood testing resulted in 4/42 positive cases (9%),
of which 3 corresponded to culture-positive results (pa-
tients A11, A12, A15; Table 1). One patient (A10) was
culture-negative and FT MTB-positive (Table 1). The diag-
nostic sensitivity and specificity of the FluoroType® MTB
PCR assay in study A was 33% and 97%, respectively.
Study B results
In this study, 9 ml samples were extracted. The rate of
blood culture positivity lay at 7/31 cases (22%). FT MTB
blood testing resulted in 6 positive cases (overall rate,
19%) of which 5 were also positive by culture (patients
B5, B6, B7, B9, B12). One patient (B10) tested blood
culture-negative and FT MTB-positive, while two sam-
ples B8 and B11 were culture positive and FT MTB
negative (Table 2). The diagnostic sensitivity and specifi-
city of the FluoroType® MTB PCR assay in study B was
71% and 96%, respectively.













bNine milliliters blood extracted.
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The diagnostic performance of the FT MTB in blood
samples was compared to blood culture results (Table 3).
The sensitivity increased from 33% with duplicate 1 ml
samples (study A) to 71% with 9 ml blood analyzed
(study B). The specificities were comparably high in both
studies-A (97%) and B (96%). Comparing 9 ml (study B)
with duplicate 1 ml blood (study A) studies, other
parameters including positive (83 vs. 75%) and negative
predictive values (92 vs. 84%) and concordance of posi-
tive and negative results (90 vs. 83%) tended to be higher
with the large blood volume analysis.
Discussion
This study was designed to evaluate the influence of
sample volume used for the extraction of DNA from
blood on PCR detection of MTB using FluoroType®
MTB test. For this, two studies on HIV-positive patients
with clinical features of blood stream TB were con-
ducted. Blood culture diagnosis indicated comparable
rates of blood stream TB in studies A (24%; see Table 1)
and B (23%; see Table 2), which agree with the rates
determined elsewhere employing HIV-positive patients
in Tanzania (18%; 15).
Blood contains numerous PCR inhibitors, among them
human DNA. Generally, removal of human DNA, which
is in great excess to microbial DNA, positively influences
the sensitivity of PCR amplification and sequencing of
broad-range [11] as well as amplification of specific tar-
get sites [12,13]. This accounts also to MTB DNA detec-
tion in blood. Restrepo et al. noticed a positive effect onTable 3 Diagnostic performance (%) of FT MTB assay against
blood volume extracted
TP FP FN TN Sensitivity, % (95% CI)
Study A (n=42) 3 1 6 32 33(8–70)
Study B (n=31) 5 1 2 23 71(29–96)
CI=Confidence Interval, FN=False Negative, FN=False Positive, NPV=Negative Predicthe sensitivity of MTB detection after separation of bac-
terial and host cell-rich fractions before DNA isolation
[14]. Here we followed the approach of human DNA re-
moval and selective enrichment of bacteria from blood
for DNA extraction by a commercial kit. By extracting a
large sample volume (9 ml), the FT MTB limit of detec-
tion (≤3 cfu/ml) could be decreased ten-fold compared
to the 1 ml extraction protocol (≤30 cfu/ml). The large
volume protocol also resulted in a higher positivity rate
of other bacteria determined by the SepsiTest 16S rRNA
gene assay and sequencing (Assay Bac, Molzym) [15]
[16] in both studies (data not shown). This additional
finding clearly shows that for the purpose of enhanced
detection sensitivities, extraction of a larger blood vol-
ume is necessary.
The higher detection sensitivity with large than small
sample volume extracts translated to improved diagnos-
tic values. While FT MTB testing with 2x 1 ml blood
extracts (study A) resulted in a rather poor sensitivity
(33%; Table 3), the 9 ml extraction protocol (study B)
provided a considerably higher diagnostic sensitivity (71%).
This diagnostic sensitivity compares well with studies
employing other molecular systems used for the identi-
fication of pathogens in blood [15,17]. The reason for
the improved diagnostic sensitivity cannot be attributed
solely to the large sample volume protocol inasmuch as
in another study Feasey et al. [9] found a sensitivity of
only 21% with the Cepheid Xpert MTB/RIF testing
employing 18 ml blood samples. Rather, when consider-
ing similar detection limits of Xpert MTB/RIF (≤10 cfu/
ml; 9) and FT MTB (≤3 cfu/ml; 10 ml protocol), the im-
proved diagnostic sensitivity observed here follows the
argumentation of a combined effect of the enrichment
of pathogen DNA and the use of a large volume of
blood [12]. A reason why FT MTB testing provided false
negative results with 2/7 blood culture positive patients
(study B; Table 2) may be attributed to the fact that the
load of MTB in blood (median, 3–8 cfu/ml; 19) is at the
limit of detection of the assay.
While blood culture is the most sensitive method,
diagnosis of blood stream TB needs culturing for several
weeks which delays in exclusion of the infection and
appropriate therapy of infected patients [4]. Here, the
median time to positive blood cultures took approx.
3 weeks (study A, 20.1 days [range, 12–32]; study B,
19.9 days [range, 15–30]; not shown). In contrast, FT
MTB direct testing for blood stream TB can be completedMTB blood culture as reference standard in relation to
Specificity, % (95% CI) PPV, % NPV, % Concordance, %
97(84–100) 75 84 83
96(79–100) 83 92 90
tive Value, PPV=Positive Predictive Value, TN=True Negative, TP=True Positive.
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For the current study, the assays were performed in
Germany, but real-time PCR analysers are available in
many laboratories in Uganda, and they are being used for
similar testing here. Thus, from the standpoint of time-to-
result, FT MTB testing can provide results in the 4.5 time-
frame even in Uganda and it is superior to culturing in
terms of time to clinically useful results. Another benefit
of the FT MTB assaying of blood is the detection of cul-
ture negative blood stream TB (one each in both studies;
see Tables 1 and 2). However, molecular testing may
add additional costs to the standard culture test which,
as is generally accepted and is shown also in this study,
is obligatory for blood stream TB diagnosis. Nonethe-
less, FT MTB testing for blood stream TB can aid culture
by the timely initiation of antimycobacterial therapy in
positive cases.
Conclusion
Analysis of MTB DNA from larger blood volumes (9 ml)
improved and gave acceptable sensitivity of direct PCR
diagnosis of blood stream TB.
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